Bristol-Myers Squibb (BMY) July 26 weekly 44.5 straddle priced into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Bristol-Myers Squibb (BMY) stock gains after raising full-year guidance
July 26, 2024 7:51 AM EDTBristol-Myers Squibb (NYSE: BMY) shares rallied more than 5% premarket Friday as the company reported a robust second quarter, surpassing Wall Street's expectations for both earnings and revenue, and raised its full-year guidance.
The pharmaceutical giant posted adjusted earnings per share (EPS) of $2.07, significantly higher than the analyst estimate of $1.64. Revenue for the quarter was also strong at $12.2 billion, beating the consensus estimate of $11.52 billion and marking a 9% increase from the same quarter last year, or an 11% rise adjusting for foreign exchange.
The company's performance was propelled by its Growth Portfolio, which saw... More
